Shimadzu
FDA Rule on Laboratory-Developed Tests Could Shake up Clinical Mass Spectrometry Space
The rule could boost Roche's planned launch of an FDA-cleared mass spec system while requiring other vendors to rethink their clinical strategies.
Japanese Consortium Launches Study to Evaluate Utility of Blood-Based Alzheimer's Markers
Shimadzu, Eisai, Oita University, and Usuki City Medical Association are studying the markers in 100 patients using Shimadzu's mass spec technology.